Professional Documents
Culture Documents
1 Sales / Income from operations (including Excise Duty) 132,935 116,083 525,368 443,274
Less: Excise duty 1,064 846 3,564 3,161
Net sales / income from operations 131,871 115,237 521,804 440,113
8 Profit before interest and exceptional items (6 + 7) 19,653 32,426 105,719 109,591
11 Exceptional items - - - -
12 Profit from ordinary activities before tax (10 - 11) 19,228 31,937 105,181 108,483
14 Net Profit from ordinary activities after tax (12 - 13) 16,587 25,316 89,331 84,608
15 Extra-ordinary items - - - -
16 Net profit for the period / year (14 - 15) 16,587 25,316 89,331 84,608
17 Paid - up equity share capital (face value Rs.5/- each) 8,463 8,442 8,463 8,442
21 Earnings per share for the period (in Rupees) per Rs.5/- share
b Non-encumbered
- Number of shares 41,317,812 41,292,812 41,317,812 41,292,812
- Percentage of shares (as a % of the total shareholding 95.16 94.89 95.16 94.89
of promoter and promoter group)
- Percentage of shares (as a % of the total share capital 24.41 24.46 24.41 24.46
of the company)
*Public Share Holding as defined under Clause 40A of Listing Agreement (excludes shares held by Promoters, Promoter Group and American Depository Receipt Holders)
All amounts in Indian Rupees lakhs, except share data
Quarter ended Year ended
Sl. No. PARTICULARS 31.03.11 31.03.10 31.03.11 31.03.10
(Unaudited) (Unaudited) (Audited) (Audited)
Segment wise revenue, results and capital employed:
1 Segment revenue :
a) Pharmaceutical Services and Active Ingredients 56,592 45,660 205,467 185,602
b) Global Generics 85,739 75,240 356,227 287,661
c) Proprietary Products 50 127 252 297
Total 142,381 121,027 561,946 473,560
2 Segment results :
Profit / (loss) before tax and interest from each segment
a) Pharmaceutical Services and Active Ingredients 10,561 5,011 30,997 33,957
b) Global Generics 15,764 21,449 96,210 80,385
c) Proprietary Products (3,875) (1,582) (11,693) (9,233)
Total 22,450 24,878 115,514 105,109
3 Capital Employed :
a) Pharmaceutical Services and Active Ingredients 177,497 136,672 177,497 136,672
b) Global Generics 265,407 166,017 265,407 166,017
c) Proprietary Products 303 2,365 303 2,365
d) Unallocated 158,793 286,395 158,793 286,395
Total 602,000 591,449 602,000 591,449
Notes:
1 Pursuant to clause 41 of the Listing Agreement, the investor complaints received, disposed off and lying unresolved for the quarter ended 31 March 2011 are given in the table below:
2 The audited results have been reviewed by the Audit Committee of the Board on 12 May 2011 and approved by the Board of Directors of the Company at their meeting held on 13 May
2011.
3 Statement of assets and liabilities All amounts in Indian Rupees lakhs, except share data
As at As at
Sl. No. PARTICULARS 31.03.11 31.03.10
(Audited) (Audited)
SHARE HOLDERS' FUNDS
a Share capital 8,463 8,442
b Reserves and surplus 593,537 583,007
LOAN FUNDS 144,473 56,317
DEFERRED TAX LIABILITY 10,076 7,501
756,549 655,267
c) Interest Service Coverage Ratio = Earnings before interest and tax / Interest expense during the period
[ Earnings before interest and tax: Profit from ordinary activities before tax + Interest expense]
5 On 31 March 2010, the Board of Directors of the Company approved a Scheme of Arrangement for issuance of Unsecured, Redeemable, Non-Convertible Bonus Debentures from general
reserves, subject to receipt of approval from shareholders, High Court of Judicature, Andhra Pradesh and other applicable regulatory authorities, as mentioned in the Scheme. During the
year, on receipt of necessary approvals and upon effectiveness of the Scheme, the Company on 24 March 2011 has issued 1,015,516,392 Bonus Debentures of Rs. 5 each fully paid-up
and carrying an interest @ 9.25% per annum, to the shareholders in the ratio of 6 bonus debentures for every equity share held by them. These debentures have been listed on the Bombay
Stock Exchange Limited and National Stock Exchange of India Limited since 7 April 2011.
6 The Board of Directors at their meeting held on 13 May 2011 have recommended a final dividend of Rs. 11.25/- per share subject to approval of shareholders.
7 The figures for the previous periods have been re-grouped/re-classified, wherever necessary, to conform with the current period classification.